Research published in an international journal and reviewed by European regulators found an approximately two fold increase in the relative risk of NAION among semaglutide users, although the overall risk remains low
Abdominal pain Constipation Decreased appetite Diarrhea Nausea Vomiting Other Potential Side Effects (less common): Acid or sour stomach Belching Bloating Dizziness Excess air or gas in the stomach Fatigue Feeling pressure in the stomach Gastritis Gastroesophageal reflux disease (GERD) Headache Heartburn Indigestion Low blood sugar (hypoglycemia) (mainly when used with insulin or sulfonylureas) Passing gas Stomach discomfort, swelling, tenderness, or upset Weight loss (can be a beneficial effect, but is also listed as a side effect) Serious Side Effects : These are rare but potentially severe side effects
That means it works by stimulating release of not one, but two unique incretin hormones produced by the human body
Currently, semaglutide, also known as Wegovy, is in short supply due to "unprecedented demand" after its approval
Significant weight loss from tirzepatide can lead to dramatic improvement or resolution of OSA
.png)
